SMALLER COMPANIES : Directors show confidence in young biotech venture

Alizyme, a budding biotech company, is at that interesting stage when early hope is turning into promise. It reached another turning point in its short existence last week when founding director and chief executive Andrew Porter took a back seat as a non-executive director.

Dr Richard Palmer, the chief operating officer, stepped up to take his place. The company also announced its preliminary results. Income, a paltry pounds 191,000, was overwhelmed by costs of pounds 1.1m to produce a deficit of pounds 1.02m after interest payments. More intriguing, however, were the heavy share purchases by directors that followed the announcement on Monday morn- ing. The full details - including Mr Porter's purchases - are detailed in the chart on the right.

What prompted the spending spree? One reason was that the directors had been unable to buy before the results. And Dr Palmer, who arrived in September, had also just been getting his feet under the table.

Even so, the purchases were unusual for the breadth of buying. There is clearly a view that the shares are undervalued right across the board - a belief emphasised by Dr Palmer: "At 32p, the shares only reflect the cash value of the business, so there is little or no perception in the market of any added value our work has created. I have a confidence and faith in the company that it's going to progress."

He says the company has already made substantial progress since July in creating value, while there is also a strong management team in place.

The question for investors, however, remains how to value a biotech company that may have many years to go before its dreams come to fruition. The question still exercises analysts. Some of the markets in which Alizyme operates have huge potential - any treatment for obesity, whether prevention or cure, would be a big money-spinner.

And it is cracking on with new trials, products and joint ventures. It has signed up a service agreement with Nichimen Corp, the Japanese trading house, and is testing several compounds for inhibiting lipase, the digestive enzyme for fats in the gut.

The shares have fallen from the 60p flotation price last June, and crept up a few pence last week to close at 37.5p. With a board this enthusiastic, the shares are worth a punt.

Start your day with The Independent, sign up for daily news emails
ebooksAn unforgettable anthology of contemporary reportage
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Digital Optimisation Executive - Marketing

£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...

Recruitment Genius: Financial Reporting Manager

£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...

Recruitment Genius: Payments Operations Assistant

£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...

Recruitment Genius: Telephone Debt Negotiator

£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...

Day In a Page

Sepp Blatter resignation: The beginning of Fifa's long road to reform?

Does Blatter's departure mean Fifa will automatically clean up its act?

Don't bet on it, says Tom Peck
Charles Kennedy: The baby of the House who grew into a Lib Dem giant

The baby of the House who grew into a Lib Dem giant

Charles Kennedy was consistently a man of the centre-left, dedicated to social justice, but was also a champion of liberty and an opponent of the nanny-state, says Baroness Williams
Syria civil war: The harrowing testament of a five-year-old victim of this endless conflict

The harrowing testament of a five-year-old victim of Syria's endless civil war

Sahar Qanbar lost her mother and brother as civilians and government soldiers fought side by side after being surrounded by brutal Islamist fighters. Robert Fisk visited her
The future of songwriting: How streaming is changing everything we know about making music

The future of songwriting

How streaming is changing everything we know about making music
William Shemin and Henry Johnson: Jewish and black soldiers receive World War I Medal of Honor amid claims of discrimination

Recognition at long last

Jewish and black soldiers who fought in WWI finally receive medals after claims of discrimination
Beating obesity: The new pacemaker which helps over-eaters

Beating obesity

The new pacemaker which helps over-eaters
9 best women's festival waterproofs

Ready for rain: 9 best women's festival waterproofs

These are the macs to keep your denim dry and your hair frizz-free(ish)
Cycling World Hour Record: Nervous Sir Bradley Wiggins ready for pain as he prepares to go distance

Wiggins worried

Nervous Sir Bradley ready for pain as he prepares to attempt cycling's World Hour Record
Liverpool close in on Milner signing

Liverpool close in on Milner signing

Reds baulk at Christian Benteke £32.5m release clause
On your feet! Spending at least two hours a day standing reduces the risk of heart attacks, cancer and diabetes, according to new research

On your feet!

Spending half the day standing 'reduces risk of heart attacks and cancer'
With scores of surgeries closing, what hope is there for the David Cameron's promise of 5,000 more GPs and a 24/7 NHS?

The big NHS question

Why are there so few new GPs when so many want to study medicine?
Big knickers are back: Thongs ain't what they used to be

Thongs ain't what they used to be

Big knickers are back
Thurston Moore interview

Thurston Moore interview

On living in London, Sonic Youth and musical memoirs
In full bloom

In full bloom

Floral print womenswear
From leading man to Elephant Man, Bradley Cooper is terrific

From leading man to Elephant Man

Bradley Cooper is terrific